Gastroenteropancreatic Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Gastroenteropancreatic Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors
This entry reports the completion of a clinical trial cohort studying well-differentiated grade 3 neuroendocrine tumors of the digestive tra…
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases [Phase 2]
Phase 2 trial evaluating adjuvant 177Lu-DOTATATE versus best supportive care after surgical resection of neuroendocrine liver metastases; th…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) [Phase 1]
Phase 1 study evaluating Debio 4126 in participants with acromegaly or functioning gastroenteropancreatic neuroendocrine tumors has been ter…
-
CLINICAL_TRIALS trial_result · 2025-09-05Clinical Trial Update: A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs [Phase 3]
A Phase 3 clinical trial compares Lutetium-177Lu oxodotreotide with Octreotide LAR in patients with gastroenteropancreatic neuroendocrine tu…
-
CLINICAL_TRIALS trial_result · 2025-09-03Clinical Trial Update: Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer [Phase 2]
Phase 2 study assessing bevacizumab in combination with FOLFIRI as second-line therapy for advanced, inoperable poorly differentiated neuroe…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-07-09Clinical Trial Update: Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors [Phase 1, Phase 2]
A pharmacokinetic study evaluating the combination of lurbinectedin and irinotecan in selected solid tumors has completed (Phase 1/Phase 2).
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
This clinical trial update reports results from a nutrition-focused study in patients with gastroenteropancreatic neuroendocrine tumors.
-
CLINICAL_TRIALS trial_result · 2025-03-03Clinical Trial Update: A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases
Clinical trial update indicating the study completed on using a transfer learning radiomics model to predict response to initial transarteri…
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. [Phase 1]
Phase 1 clinical trial evaluating the radiopharmaceutical 177Lu-PP-F11N for receptor-targeted therapy and imaging in metastatic medullary th…
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. [Phase 2]
This is a phase 2 trial evaluating the combination of platinum-doublet chemotherapy with nivolumab for gastroenteropancreatic neuroendocrine…
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors [Phase 1, Phase 2]
The document reports a completed Phase 1/Phase 2 trial evaluating Lutetium-177 dotatate in combination with metronomic capecitabine for aggr…
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors [Phase 2]
Phase 2 trial of 177Lu-DOTATATE for advanced gastroenteropancreatic neuroendocrine tumors was terminated.
-
CLINICAL_TRIALS trial_result · 2025-01-09Clinical Trial Update: Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin [Phase 2]
A phase 2 trial evaluating the combination of durvalumab and tremelimumab in advanced gastroenteropancreatic and lung-origin neuroendocrine …
-
CLINICAL_TRIALS trial_result · 2025-01-06Clinical Trial Update: A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment [NA]
A completed study evaluating whether circulating tumor DNA can be used in follow-up of patients with advanced gastroenteropancreatic or lung…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
A completed clinical trial update from Ipsen studying participants’ experiences with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)…
-
CLINICAL_TRIALS trial_result · 2024-11-27Clinical Trial Update: Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs [Phase 2]
Phase 2 study evaluating safety and dosimetry of Lutathera (lutetium-177 DOTATATE) in adolescent patients with gastroenteropancreatic neuroe…
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET [Phase 3]
Phase 3 study to evaluate Lutathera (lutetium Lu-177 dotatate) in patients with grade 2/3 advanced gastroenteropancreatic neuroendocrine tum…
-
CLINICAL_TRIALS trial_result · 2024-10-01Clinical Trial Update: Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs [Phase 3]
Phase 3 study in Chinese participants with gastroenteropancreatic neuroendocrine tumors has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors [Phase 2]
Phase 2 trial evaluating everolimus after chemoembolization for liver metastases from digestive gastroenteropancreatic neuroendocrine tumors…
-
CLINICAL_TRIALS trial_result · 2024-08-09Clinical Trial Update: A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea
This document reports the completion of a post-marketing surveillance study of Lutathera (lutetium Lu-177 dotatate) in Korean patients with …
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms [Phase 2]
Phase 2 clinical trial investigating dual 64Cu-DOTATATE and 18F-FDG PET/CT imaging for neuroendocrine neoplasms.
-
CLINICAL_TRIALS trial_result · 2021-01-14Clinical Trial Update: To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) [Phase 2]
Phase 2 trial evaluating the optimal dose of the PET imaging agent 68Ga-OPS202 in gastroenteropancreatic neuroendocrine tumors has completed…
-
CLINICAL_TRIALS trial_result · 2019-05-06Clinical Trial Update: Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET [Phase 2]
Phase 2 trial evaluating combination of Lanreotide Autogel 120mg with Temozolomide in progressive gastroenteropancreatic neuroendocrine tumo…
-
CLINICAL_TRIALS trial_result · 2019-01-22Clinical Trial Update: A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor [Phase 2]
The Phase 2 study of famitinib in advanced or metastatic gastroenteropancreatic neuroendocrine tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2018-09-11Clinical Trial Update: A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3 [Phase 2]
A Phase 2 study evaluating anlotinib in patients with Gastroenteropancreatic Neuroendocrine Tumor G3 is ongoing or not yet reported.